2023-05-03 17:47:21 ET
- ImmunoGen stock closed up a whopping ~136% on Wednesday after presenting data indicating significant improvement in progression-free and overall survival for ovarian cancer drug Elahere (mirvetuximab soravtansine-gynx).
- The company said that median PFS in the Elahere group was 5.62 months, compared to 3.98 months in the chemo group.
- The antibody-drug conjugate received accelerated approval in November 2022 .
- ImmunoGen ( NASDAQ: IMGN ) now has an over $2B market cap .
For further details see:
Why did ImmunoGen stock rocket today? Ovarian cancer drug data